<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584516</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-309</org_study_id>
    <nct_id>NCT03584516</nct_id>
  </id_info>
  <brief_title>GRAVITAS-309: Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease</brief_title>
  <official_title>GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of itacitinib in combination
      with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host
      disease (cGVHD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">October 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In Part 2 of the study, participants in the placebo group will be allowed to cross over to the experimental group after completion of the primary analysis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of dose-limiting toxicities</measure>
    <time_frame>28 days</time_frame>
    <description>To identify an appropriate dose of itacitinib in combination with corticosteroids as initial treatment for moderate or severe cGVHD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Response rate</measure>
    <time_frame>Month 6</time_frame>
    <description>Defined as the proportion of participants demonstrating a complete response (CR) or partial response (PR) per National Institutes of Health (NIH) consensus guideline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Cmax of itacitinib when administered in combination with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Maximum observed concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Cmin of itacitinib when administered in combination with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Minimum observed plasma or serum concentration over the dose interval.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 1 and Part 2: Response rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the proportion of participants who demonstrate a CR or PR per NIH consensus guideline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1: Time to response</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as the interval between randomization and first response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1 and Part 2: Duration of response</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as the interval between first response and cGVHD progression, death, malignancy relapse, or initiation of new systemic cGVHD therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1 and Part 2: Overall survival</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as the interval between the date of randomization and the date of death due to any cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1 and Part 2: Nonrelapse mortality</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as the proportion of participants who died due to causes other than malignancy relapse.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Number of treatment-emergent adverse events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Chronic Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Itacitinib + corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib administered in combination with corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + corticosteroids</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered in combination with corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>In Part 1 participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1.</description>
    <arm_group_label>Itacitinib + corticosteroids</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In Part 2, participants will receive matching placebo.</description>
    <arm_group_label>Placebo + corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.</description>
    <arm_group_label>Itacitinib + corticosteroids</arm_group_label>
    <arm_group_label>Placebo + corticosteroids</arm_group_label>
    <other_name>Medrol, Medrol Dosepak, Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.</description>
    <arm_group_label>Itacitinib + corticosteroids</arm_group_label>
    <arm_group_label>Placebo + corticosteroids</arm_group_label>
    <other_name>Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active, clinically diagnosed, moderate or severe cGVHD per NIH Consensus Criteria

          -  Underwent allogeneic stem cell transplantation (allo-HCT) from any donor human
             leukocyte antigen (HLA) type (matched-related, matched-unrelated, or mismatched
             related or unrelated donor) using any graft source (bone marrow, peripheral blood stem
             cells, or cord blood). Recipients of myeloablative or reduced intensity conditioning
             are eligible.

          -  Karnofsky Performance Status score ≥ 60%.

          -  Evidence of myeloid and platelet engraftment (ie, absolute neutrophil count ≥ 1.0 ×
             10^9/L and platelet count ≥ 25 × 10^9/L).

          -  Willingness to avoid pregnancy or fathering children based on protocol-defined
             criteria.

        Exclusion Criteria:

          -  Has received more than 3 days/72 hours of systemic corticosteroid treatment for cGVHD.

          -  Has received any other systemic treatment for cGVHD, including extracorporeal
             photopheresis (ECP). Prior and concomitant use of calcineurin inhibitors as well as
             topical/inhaled steroids is acceptable.

          -  Prior treatment with a Janus kinase (JAK) inhibitor for acute GVHD, unless the
             participant achieved complete or partial response and has been off JAK inhibitor
             treatment for at least 8 weeks before randomization.

          -  cGVHD occurring after a nonscheduled donor lymphocyte infusion (DLI) administered for
             pre-emptive treatment of malignancy recurrence. Participants who have received a
             scheduled DLI as part of their transplant procedure and not for management of
             malignancy relapse are eligible.

          -  Evidence of relapsed primary malignancy or receipt of treatment for relapse after the
             allo-HCT was performed.

          -  Corticosteroid therapy at doses &gt; 0.25 mg/kg per day methylprednisolone or equivalent
             within 7 days of randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Morariu-Zamfir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>520-626-3191</phone>
    </contact>
    <investigator>
      <last_name>Dr. Keri Maher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>626-218-2405</phone>
    </contact>
    <investigator>
      <last_name>Dr. Haris Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-721-2505</phone>
    </contact>
    <investigator>
      <last_name>Dr. Vamsi Kota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(USO) Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-827-9060</phone>
    </contact>
    <investigator>
      <last_name>Dr. Leonard Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University - Melvin and Bren Simon Cancer Center IUSCC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-948-7038</phone>
    </contact>
    <investigator>
      <last_name>Dr. Mohammad Abu Zaid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-636-4901</phone>
    </contact>
    <investigator>
      <last_name>Dr. Kellie Sprague</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-724-1124</phone>
    </contact>
    <investigator>
      <last_name>Dr. Zachariah Defilipp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-916-9461</phone>
    </contact>
    <investigator>
      <last_name>Dr. Nalini Janakiraman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>616-486-5933</phone>
    </contact>
    <investigator>
      <last_name>Dr. Sami Brake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>631-444-3577</phone>
    </contact>
    <investigator>
      <last_name>Dr. Michael Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-668-1045</phone>
    </contact>
    <investigator>
      <last_name>Dr. Mitchell Horwitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(USO) - Oncology Hematology Care - Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-751-2273</phone>
    </contact>
    <investigator>
      <last_name>Dr. James Essell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-578-4484</phone>
    </contact>
    <investigator>
      <last_name>Dr. Anna Koget</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Hillman Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-623-2393</phone>
    </contact>
    <investigator>
      <last_name>Dr. Annie Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriStart BMT</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-342-7440</phone>
    </contact>
    <investigator>
      <last_name>Dr. Carlos Bachier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-936-8422</phone>
    </contact>
    <investigator>
      <last_name>Dr. Madan Jagasia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-816-8611</phone>
    </contact>
    <investigator>
      <last_name>Dr. Aravind Ramakrishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(USO) -Texas Oncology-Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-370-1000</phone>
    </contact>
    <investigator>
      <last_name>Dr. Jana Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(USO) -Texas Oncology - Medical City Dallas Building D</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-4291</phone>
    </contact>
    <investigator>
      <last_name>Dr. Vikas Bhushan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0032 51 23 75 73 22</phone>
    </contact>
    <investigator>
      <last_name>Dr. Dries Deeren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3232177397</phone>
    </contact>
    <investigator>
      <last_name>Dr. Dimitri Breems</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3225413796</phone>
    </contact>
    <investigator>
      <last_name>Dr. Sebastian Wittnebel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0032 3 821 39 17</phone>
    </contact>
    <investigator>
      <last_name>Dr. Alain Gadisseur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ghent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>32 09 332 66 54</phone>
    </contact>
    <investigator>
      <last_name>Dr. Tessa Kerre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liege B35</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3243667201</phone>
    </contact>
    <investigator>
      <last_name>Pr. Yves Beguin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU De Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr. Patrice Chevallier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033 2 99 28 5222</phone>
    </contact>
    <investigator>
      <last_name>Dr. Marc Bernard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Card G. Carus</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 351 458 2583</phone>
    </contact>
    <investigator>
      <last_name>Dr. Jan Moritz Middeke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abteilung für Haematologie und internistische Onkologie</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0049 341 / 97 13 19 5</phone>
    </contact>
    <investigator>
      <last_name>Dr. Georg-Nikolaus Franke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 30 450 513 512</phone>
    </contact>
    <investigator>
      <last_name>Dr. Klaus A. Nogai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 3641 9 324664</phone>
    </contact>
    <investigator>
      <last_name>Dr. Inken Hilgendorf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Sebastian Kreil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>07071-29 822711</phone>
    </contact>
    <investigator>
      <last_name>Prof. Dr. Wolfgang Bethge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia, Università Politecnica delle Marche, Ancona-Italy</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>39 0715964235</phone>
    </contact>
    <investigator>
      <last_name>Prof. Attilio Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>39 62037 80331</phone>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOR Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(+39) 0916802641</phone>
    </contact>
    <investigator>
      <last_name>Dr. Rosanna Scime</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(+39) 0882410322</phone>
    </contact>
    <investigator>
      <last_name>Dr. Angelo Michele Carella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>045-8124903</phone>
    </contact>
    <investigator>
      <last_name>Dr. Fabio Benedetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48 58 349 30 70</phone>
    </contact>
    <investigator>
      <last_name>Doc Maria Bieniaszewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48225725959</phone>
    </contact>
    <investigator>
      <last_name>Dr. Grzegorz Basak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico De Santiago De Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034981950172</phone>
    </contact>
    <investigator>
      <last_name>Dr. Marta Sonia González Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U. Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34913368858</phone>
    </contact>
    <investigator>
      <last_name>Dr. Anabelle Chinea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico De Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34 961 973 838</phone>
    </contact>
    <investigator>
      <last_name>Dr. Carlos Solano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>44 2920745373</phone>
      <phone_ext>2331</phone_ext>
    </contact>
    <investigator>
      <last_name>Dr. Wendy Ingram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft-versus-host-disease</keyword>
  <keyword>itacitinib</keyword>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

